{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T07:13:56Z","timestamp":1776928436003,"version":"3.51.2"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000},"content-version":"am","delay-in-days":361,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Centre de Recherche en \u00c9pid\u00e9miologie"},{"name":"Sant\u00e9 des Populations"},{"name":"Caisse Nationale d\u2019Assurance Maladie","award":["DIR\/CABMCN-D-2016-4356"],"award-info":[{"award-number":["DIR\/CABMCN-D-2016-4356"]}]}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.revmed.2019.10.001","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T08:32:00Z","timestamp":1571992320000},"page":"89-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Naftidrofuryl dans l\u2019art\u00e9riopathie oblit\u00e9rante des membres inf\u00e9rieurs\u00a0: une revue syst\u00e9matique de la litt\u00e9rature"],"prefix":"10.1016","volume":"41","author":[{"given":"B.","family":"Bourrion","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hazard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Baltazard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Sebbag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.revmed.2019.10.001_bib0215","first-page":"38","article-title":"\u00c9pid\u00e9miologie de l\u2019art\u00e9riopathie des membres inf\u00e9rieurs","volume":"47","author":"Aboyans","year":"2018","journal-title":"Presse Medicale Paris Fr 1983"},{"issue":"Suppl 5","key":"10.1016\/j.revmed.2019.10.001_bib0220","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2165\/00003495-199100425-00005","article-title":"Coronary disease and stroke in patients with large-vessel peripheral arterial disease","volume":"42","author":"Criqui","year":"1991","journal-title":"Drugs."},{"issue":"25","key":"10.1016\/j.revmed.2019.10.001_bib0225","first-page":"1","article-title":"Appr\u00e9ciation de la pr\u00e9valence de l\u2019art\u00e9riopathie oblit\u00e9rante des membresinf\u00e9rieurs en France \u00e0 l\u2019aide de l\u2019index systolique dans une population \u00e0 risque vasculaire","volume":"38\u201346","author":"Boccalon","year":"2008","journal-title":"J Mal Vasc"},{"key":"10.1016\/j.revmed.2019.10.001_bib0230","unstructured":"ameli.fr. Affection de longue dur\u00e9e (ALD). https:\/\/www.ameli.fr\/l-assurance-maladie\/statistiques-et-publications\/donnees-statistiques\/affection-de-longue-duree-ald\/index.php. Acc\u00e8s au site le.(16\u00a0oct 2018)."},{"key":"10.1016\/j.revmed.2019.10.001_bib0235","doi-asserted-by":"crossref","unstructured":"Prise en charge de l\u2019art\u00e9riopathie chronique oblit\u00e9rante ath\u00e9roscl\u00e9reuse des membres inf\u00e9rieurs (indications m\u00e9dicamenteuses, de revascularisation et de r\u00e9\u00e9ducation). Ann Dermatol V\u00e9n\u00e9r\u00e9ologie 2007; 134(2):199-206.","DOI":"10.1016\/S0151-9638(07)91621-X"},{"key":"10.1016\/j.revmed.2019.10.001_bib0240","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Prise en charge de l\u2019art\u00e9riopathie chronique oblit\u00e9rante ath\u00e9roscl\u00e9reuse des membres inf\u00e9rieurs - Indications m\u00e9dicamenteuses, de revascularisation et de r\u00e9\u00e9ducation. https:\/\/www.has-sante.fr\/portail\/jcms\/c_272513\/fr\/prise-en-charge-de-l-arteriopathie-chronique-obliterante-atherosclereuse-des-membres-inferieurs-indications-medicamenteuses-de-revascularisation-et-de-reeducation. Acc\u00e8s au site le (16\u00a0oct 2018)"},{"issue":"2","key":"10.1016\/j.revmed.2019.10.001_bib0245","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.revmed.2006.11.004","article-title":"Traitement m\u00e9dical de l\u2019art\u00e9riopathie oblit\u00e9rante des membres inf\u00e9rieurs\u00a0: \u00e9tude de pratique professionnelle chez 262\u00a0patients","volume":"28","author":"Dumas","year":"2007","journal-title":"Rev M\u00e9decine Interne"},{"key":"10.1016\/j.revmed.2019.10.001_bib0250","series-title":"Vasodilatateurs dans l\u2019art\u00e9riopathie oblit\u00e9rante des membres inf\u00e9rieurs\u00a0: \u00e9laboration de guides M\u00e9decin et Patient\u00a0: contribution \u00e0 la Top five list fran\u00e7aise en m\u00e9decine g\u00e9n\u00e9rale [th\u00e8se]","author":"Bourrion","year":"2018"},{"key":"10.1016\/j.revmed.2019.10.001_bib0255","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. http:\/\/handbook-5-1.cochrane.org\/. Acc\u00e8s au site le (9\u00a0d\u00e9c 2017)"},{"key":"10.1016\/j.revmed.2019.10.001_bib0260","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.revmed.2019.10.001_bib0265","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.revmed.2019.10.001_bib0270","first-page":"84","article-title":"From systematic reviews to clinical recommendations for evidence-based health care: validation of revised assessment of multiple systematic reviews (R-AMSTAR) for grading of clinical relevance","volume":"4","author":"Kung","year":"2010","journal-title":"Open Dent J"},{"key":"10.1016\/j.revmed.2019.10.001_bib0275","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010\u00a0Statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"issue":"7624","key":"10.1016\/j.revmed.2019.10.001_bib0280","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"Elm","year":"2007","journal-title":"BMJ"},{"issue":"148","key":"10.1016\/j.revmed.2019.10.001_bib0285","doi-asserted-by":"crossref","first-page":"465","DOI":"10.56746\/EXERCER.2018.148.465","article-title":"B\u00e9n\u00e9fices et risques de la prescription d\u2019un traitement hom\u00e9opathique en prophylaxie antigrippale\u00a0: exemple de l\u2019influenzinum","author":"Hazard","year":"2018","journal-title":"Exercer"},{"issue":"134","key":"10.1016\/j.revmed.2019.10.001_bib0290","first-page":"282","article-title":"\u00ab\u00a0Top five list\u00a0\u00bb fran\u00e7aise en m\u00e9decine g\u00e9n\u00e9rale \u2013 Protocole de l\u2019\u00e9tude","author":"Hazard","year":"2017","journal-title":"Exercer"},{"key":"10.1016\/j.revmed.2019.10.001_bib0295","unstructured":"Medic\u2019AM. Donn\u00e9es mensuelles et annuelles sur les m\u00e9dicaments rembours\u00e9s par l\u2019Assurance Maladie. https:\/\/www.ameli.fr\/l-assurance-maladie\/statistiques-et-publications\/donnees-statistiques\/medicament\/medic-am\/medic-am-mensuel-2017.php. Acc\u00e8s au site le.(22\u00a0oct 2018)."},{"issue":"3","key":"10.1016\/j.revmed.2019.10.001_bib0300","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s002280000114","article-title":"Oral vasoactive medication in intermittent claudication: utile or futile?","volume":"56","author":"De Backer","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.revmed.2019.10.001_bib0305","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2165\/00003495-200059050-00003","article-title":"Pharmacological management of intermittent claudication: a meta-analysis of randomised trials","volume":"59","author":"Moher","year":"2000","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.revmed.2019.10.001_bib0310","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0003-3928(01)00016-6","article-title":"Effet du naftidrofuryl sur la distance de marche physiologique chez des patients au stade de claudication intermittente","volume":"50","author":"Boccalon","year":"2001","journal-title":"Ann Cardiol Angeiol (Paris)"},{"issue":"1","key":"10.1016\/j.revmed.2019.10.001_bib0315","first-page":"58","article-title":"A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS)","volume":"20","author":"Kieffer","year":"2001","journal-title":"Int Angiol J Int Union Angiol"},{"key":"10.1016\/j.revmed.2019.10.001_bib0320","first-page":"CD001368","article-title":"Naftidrofuryl for intermittent claudication","volume":"12","author":"De Backer","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.revmed.2019.10.001_bib0325","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2165\/00002512-200522110-00006","article-title":"Naftidrofuryl: a review of its use in the treatment of intermittent claudication","volume":"22","author":"Goldsmith","year":"2005","journal-title":"Drugs Aging"},{"key":"10.1016\/j.revmed.2019.10.001_bib0330","first-page":"A74","article-title":"Development of vascular wall stiffness parameters in diabetes mellitus type II - Evaluation of therapeutic effect of sulodexide vs. naftidrofuryl","volume":"37","author":"J.M.","year":"2010","journal-title":"Pathophysiol Haemost Thromb"},{"issue":"4","key":"10.1016\/j.revmed.2019.10.001_bib0335","doi-asserted-by":"crossref","first-page":"296","DOI":"10.2174\/157340309789317823","article-title":"Current approach to the diagnosis and treatment of femoral-popliteal arterial disease. A systematic review","volume":"5","author":"C.K.","year":"2009","journal-title":"Curr Cardiol Rev"},{"issue":"40","key":"10.1016\/j.revmed.2019.10.001_bib0340","first-page":"1","article-title":"A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease","volume":"15","author":"Squires","year":"2011","journal-title":"Health Technol Assess Winch Engl"},{"issue":"13","key":"10.1016\/j.revmed.2019.10.001_bib0345","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/bjs.9357","article-title":"Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication","volume":"100","author":"Roset","year":"2013","journal-title":"Br J Surg"},{"issue":"4","key":"10.1016\/j.revmed.2019.10.001_bib0350","first-page":"288","article-title":"Naftidrofuryl in quality of life (NIQOL). A Belgian study","volume":"20","author":"D\u2019Hooge","year":"2001","journal-title":"Int Angiol J Int Union Angiol"},{"issue":"1","key":"10.1016\/j.revmed.2019.10.001_bib0355","first-page":"20","article-title":"Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program","volume":"21","author":"Spengel","year":"2002","journal-title":"Int Angiol J Int Union Angiol"},{"issue":"3","key":"10.1016\/j.revmed.2019.10.001_bib0360","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2174\/157016110791112278","article-title":"Silence of the limbs pharmacological symptomatic treatment of intermittent claudication","volume":"8","author":"De Backer","year":"2010","journal-title":"Curr Vasc Pharmacol"},{"issue":"12","key":"10.1016\/j.revmed.2019.10.001_bib0365","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1002\/bjs.8895","article-title":"Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication","volume":"99","author":"Stevens","year":"2012","journal-title":"Br J Surg"},{"issue":"Suppl 2","key":"10.1016\/j.revmed.2019.10.001_bib0370","first-page":"17","article-title":"[Clinical studies in peripheral arterial occlusive disease: update from the aspects of a meta-narrative review]","volume":"20","author":"Melzer","year":"2013","journal-title":"Forsch Komplementarmedizin 2006"},{"issue":"4","key":"10.1016\/j.revmed.2019.10.001_bib0375","first-page":"27","article-title":"[Use of naftidrofuryl in angiology]","volume":"20","author":"Kuznetsov","year":"2014","journal-title":"Angiol Sosud Khirurgiia Angiol Vasc Surg"},{"key":"10.1016\/j.revmed.2019.10.001_bib0380","doi-asserted-by":"crossref","first-page":"b603","DOI":"10.1136\/bmj.b603","article-title":"Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data","volume":"338","author":"De Backer","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.revmed.2019.10.001_bib0385","unstructured":"R\u00e9sum\u00e9 des Caract\u00e9ristiques du Produit. http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/rcp\/R0231772.htm#Rcp_4_4_MisesEnGarde_1. Acc\u00e8s au site le.(6\u00a0ao\u00fbt 2019)."},{"issue":"7","key":"10.1016\/j.revmed.2019.10.001_bib0390","first-page":"CD000990","article-title":"Exercise for intermittent claudication","author":"Lane","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.revmed.2019.10.001_bib0395","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/heartjnl-2015-308773","article-title":"Physical activity in the prevention of coronary heart disease: implications for the clinician","volume":"102","author":"Varghese","year":"2016","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.revmed.2019.10.001_bib0400","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0002-9343(03)00010-X","article-title":"Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease","volume":"114","author":"Mondillo","year":"2003","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.revmed.2019.10.001_bib0405","first-page":"CD000123","article-title":"Lipid-lowering for peripheral arterial disease of the lower limb","author":"Aung","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.revmed.2019.10.001_bib0410","first-page":"CD001272","article-title":"Antiplatelet agents for intermittent claudication","author":"Wong","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.revmed.2019.10.001_bib0415","series-title":"Efficacit\u00e9 et tol\u00e9rance des anticholinest\u00e9rasiques et de la m\u00e9mantine dans les troubles cognitifs l\u00e9gers et la maladie d\u2019Alzheimer\u00a0: \u00e9laboration de guides m\u00e9decin et patient [th\u00e8se]","author":"Pallu de Beaupuy-d\u2019Antho\u00fcard de Vraincourt","year":"2017"},{"key":"10.1016\/j.revmed.2019.10.001_bib0210","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-6-25","article-title":"The fading of reported effectiveness. A meta-analysis of randomised controlled trials","volume":"6","author":"Gehr","year":"2006","journal-title":"BMC Med Res Methodol"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866319306599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866319306599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:41:54Z","timestamp":1759336914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866319306599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0248866319306599"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2019.10.001","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Naftidrofuryl dans l\u2019art\u00e9riopathie oblit\u00e9rante des membres inf\u00e9rieurs\u00a0: une revue syst\u00e9matique de la litt\u00e9rature","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2019.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}